In today’s recent session, 2.0 million shares of the Humacyte Inc (NASDAQ:HUMA) have been traded, and its beta is 1.33. Most recently the company’s share price was $5.30, and it changed around -$0.2 or -3.55% from the last close, which brings the market valuation of the company to $709.69M. HUMA at last check was trading at a discount to its 52-week high of $9.97, offering almost -88.11% off that amount. The share price’s 52-week low was $2.48, which indicates that the recent value has risen by an impressive 53.21% since then. We note from Humacyte Inc’s average daily trading volume that its 10-day average is 12.85 million shares, with the 3-month average coming to 4.68 million.
Humacyte Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended HUMA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Humacyte Inc is expected to report earnings per share of -0.26 for the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA has been showing red trend so far today with a performance of -3.55% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 5.66 on recent trading dayincreased the stock’s daily price by 6.36%. The company’s shares are currently up 86.80% year-to-date, but still up 14.33% over the last five days. On the other hand, Humacyte Inc (NASDAQ:HUMA) is 20.57% up in the 30-day period. We can see from the shorts that 21.96 million shares have been sold at a short interest cover period of 7.53 day(s).
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 33.75% from its current value. Analyst projections state that HUMA is forecast to be at a low of $6 and a high of $10.
Humacyte Inc (HUMA) estimates and forecasts
Humacyte Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -1.21 percent over the past six months and at a -18.69% annual growth rate that is well below the industry average of 16.70%.
4 analysts expect Humacyte Inc to make 1.78M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
HUMA Dividends
Humacyte Inc’s next quarterly earnings report is expected to be released in January.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 26.87% of Humacyte Inc shares, and 30.01% of them are in the hands of institutional investors. The stock currently has a share float of 41.04%. Humacyte Inc stock is held by 194.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 6.5961% of the shares, which is about 7.14 million shares worth $34.27 million.
VANGUARD GROUP INC, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
